Melphalan

Melphalan forms covalent bonds with DNA, creating cross‑links that block DNA replication and transcription. This interference triggers cell‑cycle arrest and apoptosis, especially in fast‑growing tumor cells, while relatively sparing normal cells that divide less frequently.

The dose of melphalan is individualized and determined by the prescribing physician based on factors such as the specific cancer type, disease stage, patient weight, renal function and prior treatment history. No standard dose is provided here; clinicians calculate the appropriate regimen for each patient.

Safety data for melphalan during pregnancy and lactation are limited, and the drug is generally considered contraindicated because of its potential teratogenic and cytotoxic effects. Women of childbearing potential should use effective contraception, and breastfeeding is not recommended while receiving melphalan.

To order melphalan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Melphalan belongs to the nitrogen‑mustard subclass of alkylating agents and shares a similar DNA‑cross‑linking mechanism with drugs like cyclophosphamide. Compared with some older agents, melphalan often has a higher potency in certain hematologic malignancies but may also present a distinct toxicity profile, requiring individualized risk‑benefit assessment.

Melphalan for injection should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. Follow standard aseptic techniques when preparing the infusion, and dispose of any unused solution according to local hazardous‑waste regulations.

Melphalan is administered intravenously by a qualified healthcare professional. The drug is typically diluted in a compatible IV solution and infused over a prescribed period, which may range from a few minutes to several hours depending on the treatment protocol and patient tolerance.

Serious risks include severe bone‑marrow suppression leading to life‑threatening infections, secondary malignancies such as therapy‑related leukemia, renal toxicity, pulmonary fibrosis, and hemorrhagic cystitis. Patients should be monitored closely for signs of infection, blood‑count abnormalities and organ dysfunction throughout therapy.

Melphalan is contraindicated in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in those with severe bone‑marrow failure, uncontrolled infections, or significant renal impairment. It should also be avoided in pregnant women and in individuals who cannot adhere to required monitoring and supportive care.